Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker
Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to = 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >=...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Pontillo, Claudia Zhang, Zhen-Yu Schanstra, Joost P Jacobs, Lotte Zürbig, Petra Thijs, Lutgarde Ramirez-Torrez, Adela Heerspink, Hiddo JL Lindhardt, Morten Klein, Ronald Orchard, Trevor Porta, Massimo Bilous, Rudolf W Charturvedi, Nishi Rossing, Peter Vlahou, Antonia Schepers, Eva Glorieux, Griet Mullen, William Delles, Christian Verhamme, Peter Vanholder, Raymond Staessen, Jan A Mischak, Harald Jankowski, Joachim |
| description | Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to = 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.
Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P < 0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to = 1.23; P = 1.20; P = 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P |
| format | Article |
| fullrecord | <record><control><sourceid>ghent</sourceid><recordid>TN_cdi_ghent_librecat_oai_archive_ugent_be_8542779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_archive_ugent_be_8542779</sourcerecordid><originalsourceid>FETCH-ghent_librecat_oai_archive_ugent_be_85427793</originalsourceid><addsrcrecordid>eNqdi8uKwkAQAIdFYUX9h_6AFcZJNMnZB4IXD7vnoTNpk_Yxs_SMQv5eBQ973lMVFPWhRiZfljNt8mrwxz_VNMaT1npeLBeVLkfq5yDUsEscPIQjuE6CZwdnbjz10HAkjAQxYUuQQd3Dar82RfYFCDdhj9LDr4RE4fq8ag5XlDPJRA2PeIk0fXOszHbzvdrN2o58sheuhRwmG5Atiuv4TvbWvlJNtlzkpiiq7F_TA6RuTlQ</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Ghent University Academic Bibliography</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Pontillo, Claudia ; Zhang, Zhen-Yu ; Schanstra, Joost P ; Jacobs, Lotte ; Zürbig, Petra ; Thijs, Lutgarde ; Ramirez-Torrez, Adela ; Heerspink, Hiddo JL ; Lindhardt, Morten ; Klein, Ronald ; Orchard, Trevor ; Porta, Massimo ; Bilous, Rudolf W ; Charturvedi, Nishi ; Rossing, Peter ; Vlahou, Antonia ; Schepers, Eva ; Glorieux, Griet ; Mullen, William ; Delles, Christian ; Verhamme, Peter ; Vanholder, Raymond ; Staessen, Jan A ; Mischak, Harald ; Jankowski, Joachim</creator><creatorcontrib>Pontillo, Claudia ; Zhang, Zhen-Yu ; Schanstra, Joost P ; Jacobs, Lotte ; Zürbig, Petra ; Thijs, Lutgarde ; Ramirez-Torrez, Adela ; Heerspink, Hiddo JL ; Lindhardt, Morten ; Klein, Ronald ; Orchard, Trevor ; Porta, Massimo ; Bilous, Rudolf W ; Charturvedi, Nishi ; Rossing, Peter ; Vlahou, Antonia ; Schepers, Eva ; Glorieux, Griet ; Mullen, William ; Delles, Christian ; Verhamme, Peter ; Vanholder, Raymond ; Staessen, Jan A ; Mischak, Harald ; Jankowski, Joachim</creatorcontrib><description><![CDATA[Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to <60 ml/min per 1.73 m(2).
Methods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.
Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P < 0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to <60 ml/min per 1.73 m(2)), and 172 experienced an endpoint sustained over follow-up. The risk of a first and sustained renal endpoint increased with UAE (hazard ratio >= 1.23; P <= 0.043) and CKD273 (>= 1.20; P <= 0.031). UAE (>= 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P <= 0.0001 for difference between UAE and CKD273 in proportion of correctly classified individuals). As continuous markers, CKD273 (P = 0.039), but not UAE (P = 0.065), increased the integrated discrimination improvement, while both UAE and CKD273 improved the net reclassification index (P <= 0.0003), except for UAE per threshold (P = 0.086).
Discussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.]]></description><identifier>ISSN: 2468-0249</identifier><identifier>EISSN: 2468-0249</identifier><language>eng</language><subject>biomarker ; CANDESARTAN ; chronic kidney disease ; clinical science ; FIBRINOGEN ; FIBROSIS ; GLOMERULAR-FILTRATION-RATE ; Medicine and Health Sciences ; MICROALBUMINURIA ; peptidomics ; PREVENTION ; PROGRESSION ; proteomics ; RECLASSIFICATION ; RETINOPATHY ; TRIAL</subject><creationdate>2017</creationdate><rights>Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,778,782,4012,27843</link.rule.ids></links><search><creatorcontrib>Pontillo, Claudia</creatorcontrib><creatorcontrib>Zhang, Zhen-Yu</creatorcontrib><creatorcontrib>Schanstra, Joost P</creatorcontrib><creatorcontrib>Jacobs, Lotte</creatorcontrib><creatorcontrib>Zürbig, Petra</creatorcontrib><creatorcontrib>Thijs, Lutgarde</creatorcontrib><creatorcontrib>Ramirez-Torrez, Adela</creatorcontrib><creatorcontrib>Heerspink, Hiddo JL</creatorcontrib><creatorcontrib>Lindhardt, Morten</creatorcontrib><creatorcontrib>Klein, Ronald</creatorcontrib><creatorcontrib>Orchard, Trevor</creatorcontrib><creatorcontrib>Porta, Massimo</creatorcontrib><creatorcontrib>Bilous, Rudolf W</creatorcontrib><creatorcontrib>Charturvedi, Nishi</creatorcontrib><creatorcontrib>Rossing, Peter</creatorcontrib><creatorcontrib>Vlahou, Antonia</creatorcontrib><creatorcontrib>Schepers, Eva</creatorcontrib><creatorcontrib>Glorieux, Griet</creatorcontrib><creatorcontrib>Mullen, William</creatorcontrib><creatorcontrib>Delles, Christian</creatorcontrib><creatorcontrib>Verhamme, Peter</creatorcontrib><creatorcontrib>Vanholder, Raymond</creatorcontrib><creatorcontrib>Staessen, Jan A</creatorcontrib><creatorcontrib>Mischak, Harald</creatorcontrib><creatorcontrib>Jankowski, Joachim</creatorcontrib><title>Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker</title><description><![CDATA[Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to <60 ml/min per 1.73 m(2).
Methods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.
Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P < 0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to <60 ml/min per 1.73 m(2)), and 172 experienced an endpoint sustained over follow-up. The risk of a first and sustained renal endpoint increased with UAE (hazard ratio >= 1.23; P <= 0.043) and CKD273 (>= 1.20; P <= 0.031). UAE (>= 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P <= 0.0001 for difference between UAE and CKD273 in proportion of correctly classified individuals). As continuous markers, CKD273 (P = 0.039), but not UAE (P = 0.065), increased the integrated discrimination improvement, while both UAE and CKD273 improved the net reclassification index (P <= 0.0003), except for UAE per threshold (P = 0.086).
Discussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.]]></description><subject>biomarker</subject><subject>CANDESARTAN</subject><subject>chronic kidney disease</subject><subject>clinical science</subject><subject>FIBRINOGEN</subject><subject>FIBROSIS</subject><subject>GLOMERULAR-FILTRATION-RATE</subject><subject>Medicine and Health Sciences</subject><subject>MICROALBUMINURIA</subject><subject>peptidomics</subject><subject>PREVENTION</subject><subject>PROGRESSION</subject><subject>proteomics</subject><subject>RECLASSIFICATION</subject><subject>RETINOPATHY</subject><subject>TRIAL</subject><issn>2468-0249</issn><issn>2468-0249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ADGLB</sourceid><recordid>eNqdi8uKwkAQAIdFYUX9h_6AFcZJNMnZB4IXD7vnoTNpk_Yxs_SMQv5eBQ973lMVFPWhRiZfljNt8mrwxz_VNMaT1npeLBeVLkfq5yDUsEscPIQjuE6CZwdnbjz10HAkjAQxYUuQQd3Dar82RfYFCDdhj9LDr4RE4fq8ag5XlDPJRA2PeIk0fXOszHbzvdrN2o58sheuhRwmG5Atiuv4TvbWvlJNtlzkpiiq7F_TA6RuTlQ</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Pontillo, Claudia</creator><creator>Zhang, Zhen-Yu</creator><creator>Schanstra, Joost P</creator><creator>Jacobs, Lotte</creator><creator>Zürbig, Petra</creator><creator>Thijs, Lutgarde</creator><creator>Ramirez-Torrez, Adela</creator><creator>Heerspink, Hiddo JL</creator><creator>Lindhardt, Morten</creator><creator>Klein, Ronald</creator><creator>Orchard, Trevor</creator><creator>Porta, Massimo</creator><creator>Bilous, Rudolf W</creator><creator>Charturvedi, Nishi</creator><creator>Rossing, Peter</creator><creator>Vlahou, Antonia</creator><creator>Schepers, Eva</creator><creator>Glorieux, Griet</creator><creator>Mullen, William</creator><creator>Delles, Christian</creator><creator>Verhamme, Peter</creator><creator>Vanholder, Raymond</creator><creator>Staessen, Jan A</creator><creator>Mischak, Harald</creator><creator>Jankowski, Joachim</creator><scope>ADGLB</scope></search><sort><creationdate>2017</creationdate><title>Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker</title><author>Pontillo, Claudia ; Zhang, Zhen-Yu ; Schanstra, Joost P ; Jacobs, Lotte ; Zürbig, Petra ; Thijs, Lutgarde ; Ramirez-Torrez, Adela ; Heerspink, Hiddo JL ; Lindhardt, Morten ; Klein, Ronald ; Orchard, Trevor ; Porta, Massimo ; Bilous, Rudolf W ; Charturvedi, Nishi ; Rossing, Peter ; Vlahou, Antonia ; Schepers, Eva ; Glorieux, Griet ; Mullen, William ; Delles, Christian ; Verhamme, Peter ; Vanholder, Raymond ; Staessen, Jan A ; Mischak, Harald ; Jankowski, Joachim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-ghent_librecat_oai_archive_ugent_be_85427793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>biomarker</topic><topic>CANDESARTAN</topic><topic>chronic kidney disease</topic><topic>clinical science</topic><topic>FIBRINOGEN</topic><topic>FIBROSIS</topic><topic>GLOMERULAR-FILTRATION-RATE</topic><topic>Medicine and Health Sciences</topic><topic>MICROALBUMINURIA</topic><topic>peptidomics</topic><topic>PREVENTION</topic><topic>PROGRESSION</topic><topic>proteomics</topic><topic>RECLASSIFICATION</topic><topic>RETINOPATHY</topic><topic>TRIAL</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pontillo, Claudia</creatorcontrib><creatorcontrib>Zhang, Zhen-Yu</creatorcontrib><creatorcontrib>Schanstra, Joost P</creatorcontrib><creatorcontrib>Jacobs, Lotte</creatorcontrib><creatorcontrib>Zürbig, Petra</creatorcontrib><creatorcontrib>Thijs, Lutgarde</creatorcontrib><creatorcontrib>Ramirez-Torrez, Adela</creatorcontrib><creatorcontrib>Heerspink, Hiddo JL</creatorcontrib><creatorcontrib>Lindhardt, Morten</creatorcontrib><creatorcontrib>Klein, Ronald</creatorcontrib><creatorcontrib>Orchard, Trevor</creatorcontrib><creatorcontrib>Porta, Massimo</creatorcontrib><creatorcontrib>Bilous, Rudolf W</creatorcontrib><creatorcontrib>Charturvedi, Nishi</creatorcontrib><creatorcontrib>Rossing, Peter</creatorcontrib><creatorcontrib>Vlahou, Antonia</creatorcontrib><creatorcontrib>Schepers, Eva</creatorcontrib><creatorcontrib>Glorieux, Griet</creatorcontrib><creatorcontrib>Mullen, William</creatorcontrib><creatorcontrib>Delles, Christian</creatorcontrib><creatorcontrib>Verhamme, Peter</creatorcontrib><creatorcontrib>Vanholder, Raymond</creatorcontrib><creatorcontrib>Staessen, Jan A</creatorcontrib><creatorcontrib>Mischak, Harald</creatorcontrib><creatorcontrib>Jankowski, Joachim</creatorcontrib><collection>Ghent University Academic Bibliography</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pontillo, Claudia</au><au>Zhang, Zhen-Yu</au><au>Schanstra, Joost P</au><au>Jacobs, Lotte</au><au>Zürbig, Petra</au><au>Thijs, Lutgarde</au><au>Ramirez-Torrez, Adela</au><au>Heerspink, Hiddo JL</au><au>Lindhardt, Morten</au><au>Klein, Ronald</au><au>Orchard, Trevor</au><au>Porta, Massimo</au><au>Bilous, Rudolf W</au><au>Charturvedi, Nishi</au><au>Rossing, Peter</au><au>Vlahou, Antonia</au><au>Schepers, Eva</au><au>Glorieux, Griet</au><au>Mullen, William</au><au>Delles, Christian</au><au>Verhamme, Peter</au><au>Vanholder, Raymond</au><au>Staessen, Jan A</au><au>Mischak, Harald</au><au>Jankowski, Joachim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker</atitle><date>2017</date><risdate>2017</risdate><issn>2468-0249</issn><eissn>2468-0249</eissn><abstract><![CDATA[Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to <60 ml/min per 1.73 m(2).
Methods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.
Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P < 0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to <60 ml/min per 1.73 m(2)), and 172 experienced an endpoint sustained over follow-up. The risk of a first and sustained renal endpoint increased with UAE (hazard ratio >= 1.23; P <= 0.043) and CKD273 (>= 1.20; P <= 0.031). UAE (>= 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P <= 0.0001 for difference between UAE and CKD273 in proportion of correctly classified individuals). As continuous markers, CKD273 (P = 0.039), but not UAE (P = 0.065), increased the integrated discrimination improvement, while both UAE and CKD273 improved the net reclassification index (P <= 0.0003), except for UAE per threshold (P = 0.086).
Discussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.]]></abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2468-0249 |
| ispartof | |
| issn | 2468-0249 2468-0249 |
| language | eng |
| recordid | cdi_ghent_librecat_oai_archive_ugent_be_8542779 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Ghent University Academic Bibliography; PubMed Central; Alma/SFX Local Collection |
| subjects | biomarker CANDESARTAN chronic kidney disease clinical science FIBRINOGEN FIBROSIS GLOMERULAR-FILTRATION-RATE Medicine and Health Sciences MICROALBUMINURIA peptidomics PREVENTION PROGRESSION proteomics RECLASSIFICATION RETINOPATHY TRIAL |
| title | Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A12%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-ghent&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20chronic%20kidney%20disease%20stage%203%20by%20CKD273,%20a%20urinary%20proteomic%20biomarker&rft.au=Pontillo,%20Claudia&rft.date=2017&rft.issn=2468-0249&rft.eissn=2468-0249&rft_id=info:doi/&rft_dat=%3Cghent%3Eoai_archive_ugent_be_8542779%3C/ghent%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |